ArticleArthritis care & research2014
Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
Article in Arthritis care & research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Impact of National Institutes of Health Gastrointestinal PROMIS Measures in Clinical Practice: Results of a Multicenter Controlled Trial.The American journal of gastroenterology · 2016Trial
- Gastrointestinal Symptoms and Psychological Conditions: A Literature Review with Emphasis on the Evidence in Military Personnel from China.Advances in therapy · 2025Review
- Patient-reported outcome instruments in clinical trials of systemic sclerosis.Journal of scleroderma and related disorders · 2020Review
- Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms.Gastroenterology · 2020Article
- Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints.Cannabis and cannabinoid research · 2020Article
- Colonic and Anorectal Manifestations of Systemic Sclerosis.Current gastroenterology reports · 2019Review
- An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.Journal of scleroderma and related disorders · 2019Article
- Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans.The American journal of gastroenterology · 2018Article
- Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics.Integrative medicine research · 2018Article
- Prevalence of and Factors Associated With Fecal Incontinence: Results From a Population-Based Survey.Gastroenterology · 2018Article
- Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.Journal of neurogastroenterology and motility · 2018Article
- Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.Alimentary pharmacology & therapeutics · 2017Review
- Management of gastrointestinal involvement in scleroderma.Current treatment options in rheumatology · 2015Article
- Computer-generated vs. physician-documented history of present illness (HPI): results of a blinded comparison.The American journal of gastroenterology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveGastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc; scleroderma). The Patient-Reported Outcomes Measurement Information System (PROMIS) GI symptom item bank captures upper and lower GI symptoms (reflux, disrupted swallowing, nausea/vomiting, belly pain, gas/bloating/flatulence, diarrhea, constipation, and fecal incontinence). The objective of this study was to evaluate the construct validity of the PROMIS GI bank in SSc.
methodsA total of 167 patients with SSc were administered the PROMIS GI bank and the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (GIT 2.0) instrument. GIT 2.0 is a multi-item instrument that measures SSc-associated GI symptoms. Product-moment correlations and a multitrait-multimethod analysis of the PROMIS GI scales with the GIT 2.0 symptom scales were used to evaluate convergent and discriminant validity.
resultsPatients with SSc GI involvement had PROMIS GI scale scores 0.2-0.7 SD worse than the US general population. Correlations among scales measuring the same domains for the PROMIS GI and GIT 2.0 measures were large, ranging from 0.61 to 0.87 (average r = 0.77). The average correlation between different symptom scales was 0.22, supporting discriminant validity.
conclusionThis study provides support for the construct validity of the PROMIS GI scales in SSc. Future research is needed to assess the responsiveness to change of these scales in patients with SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.